西洛他唑对小鼠慢性缺血性脑损伤的保护作用及机制

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (2): 130-134.

西洛他唑对小鼠慢性缺血性脑损伤的保护作用及机制

叶夷露¹, 张琦¹, 陈丽萍², 张建亭¹, 张晓华¹, 俞月萍¹, 魏尔清³

¹浙江医学高等专科学校,杭州 310053,浙江;
²浙江衢州学院医学系,衢州 324000,浙江;
³浙江大学医学院,杭州 310058,浙江

收稿日期:2009-11-03 修回日期:2010-01-14 出版日期:2010-02-26 发布日期:2020-09-18
通讯作者: 张琦,女,硕士,副教授,硕导,主要从事药理学教学和神经药理学研究。Tel: 0571-87692673 E-mail: zhangqiwzh@163.com
作者简介:叶夷露,女,硕士,讲师,主要从事药理学教学和神经药理学研究。Tel: 0571-87692678 E-mail: yeyilu1006@126.com
基金资助:
浙江省卫生厅科研项目(2008B034);浙江医学高等专科学校自然科学基金(2006xz01)

Protective effects of cilostazol on the chronic ischemic brain injury in mice and its action mechanism

YE Yi-lu¹, ZHANG Qi¹, ZHANG Jian-ting¹, ZHANG Xiao-hua¹, YU Yue-ping¹, WEI Er-qing²

¹ Zhejiang Medical College, Hangzhou 310053, Zhejiang,China;
² School of Medicine, Zhejiang University, Hangzhou 310058, Zhejiang,China

Received:2009-11-03 Revised:2010-01-14 Online:2010-02-26 Published:2020-09-18

摘要/Abstract

摘要： 目的:观察西洛他唑对小鼠慢性缺血性脑损伤的保护作用,探讨其与促血管生成的关系。方法:以大脑中动脉栓塞方法诱导小鼠局灶性脑缺血,缺血后1、4、7 h 和术后1～14 d 腹腔注射西洛他唑(10 mg/kg),每天一次,观察缺血后 35 d 西洛他唑对神经症状评分、斜板角度、脑梗死体积、神经元密度和缺血侧血管内皮生长因子(VEGF)、血管内皮生长因子受体2(Flk-1)表达的作用。结果:西洛他唑能降低缺血后神经症状评分,提高斜板角度,减少脑梗死体积,增加存活神经元密度和VEGF、Flk-1表达的数目。结论:西洛他唑对小鼠慢性局灶性脑缺血具有保护作用,其作用机制可能与诱导缺血侧VEGF、Flk-1表达,促进血管生成有关。

关键词: 西洛他唑, 血管内皮生长因子(VEGF), 血管内皮生长因子受体2(Flk-1), 脑缺血

Abstract: AIM: To observe the protective effects of cilostazol on chronic ischemic brain injury in mice and the relationship to angiogenesis. METHODS: Focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO). Cilostazol (10 mg/kg) was i.p. injected at 1, 4, 7 h and 1-14 d once a day after ischemia. The neurological deficits, angle in inclined board test, infarct volume, neuron density, and the expressions of VEGF and Flk-1 in ischemic region were determined at the 35 d after ischemia. RESULTS: Cilostazol (10 mg/kg) significantly reduced the neurological deficits and infarct volume, and increased the angle in inclined board test, the neuron density, and the expressions of VEGF and Flk-1. CONCLUSION: Cilostazol has neuroprotective effect on chronic ischemic brain injury in mice, which may relate to angiogenesis via inducing the expressions of VEGF and Flk-1.

Key words: Cilostazol, Vascular endothelial growth factor (VEGF), Vascular endothelial growth factor receptor 2 (Flk-1), Cerebral ischemia

中图分类号:

R965.2

叶夷露, 张琦, 陈丽萍, 张建亭, 张晓华, 俞月萍, 魏尔清. 西洛他唑对小鼠慢性缺血性脑损伤的保护作用及机制[J]. 中国临床药理学与治疗学, 2010, 15(2): 130-134.

YE Yi-lu, ZHANG Qi, ZHANG Jian-ting, ZHANG Xiao-hua, YU Yue-ping, WEI Er-qing. Protective effects of cilostazol on the chronic ischemic brain injury in mice and its action mechanism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 130-134.

参考文献

[1] 韦建瑞,李彪,黎庆梅,等. 西洛他唑与氯吡格雷联合治疗对非ST段抬高急性冠脉综合征血小板膜糖蛋白的影响[J]. 中国临床药理学与治疗学, 2008,13(5):557-562.
[2] Shalhoub J, Davies AH, Franklin IJ. Cilostazol may improve outcome in critical limb ischemia[J]. Int Angiol, 2009,28(5):363-366.
[3] 罗景慧,林永成,陈志良,等. 磷酸二酯酶3型抑制剂西洛他唑对TNF-1诱导人脐静脉内皮细胞释放可溶性粘附分子的影响[J]. 中国临床药理学与治疗学, 2003,8(6):621-626.
[4] Nonaka Y, Koumura A, Hyakkoku K, et al. Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone[J]. J Pharmacol Exp Ther, 2009,330(1):13-22.
[5] Nonaka Y, Tsuruma K, Shimazawa M, et al. Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage[J]. Neurosci Lett, 2009,452(2):156-161.
[6] Ye YL, Shi WZ, Zhang WP, et al. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries[J]. Eur J Pharmacol, 2007,557(1):23-31.
[7] Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats[J]. Stroke, 1989,20(1):84-91.
[8] Yonemori F, Yamaguchi T, Yamada H, et al. Evaluation of a motor deficit after chronic focal cerebral ischemia in rats[J]. J Cereb Blood Flow Metab, 1998,18(10):1099-1106.
[9] Lai DM, Tu YK, Liu IM, et al. Increase of adenosine A1 receptor gene expression in cerebral ischemia of Wistar rats[J]. Neurosci Lett, 2005,387(2):59-61.
[10] Meininger CJ, Schelling ME, Granger HJ. Adenosine and hypoxia stimulate proliferation and migration of endothelial cells[J]. Am J Physiol, 1988,255(3 Pt 2):H554-562.
[11] Gessi S, Fogli E, Sacchetto V, et al. Adenosine modulates HIF-1{alpha}, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells[J]. Arterioscler Thromb Vasc Biol, 30(1):90-97.
[12] Pueyo ME, Chen Y, D'Angelo G, et al. Regulation of vascular endothelial growth factor expression by cAMP in rat aortic smooth muscle cells[J]. Exp Cell Res, 1998,238(2):354-358.
[13] Ikeda U, Ikeda M, Kano S, et al. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells[J]. Eur J Pharmacol, 1996,314(1/2):197-202.
[14] Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis[J]. J Clin Invest, 1997,99(11):2625-2634.
[15] Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney[J]. Kidney Int, 1992,42(6):1457-1461.
[16] Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells[J]. Gene Ther, 2001,8(23):1801-1807.
[17] Levy AP, Levy NS, Wegner S, et al. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia[J]. J Biol Chem, 1995,270(22):13333-13340.
[18] Mu D, Jiang X, Sheldon RA, et al. Regulation of hypoxia-inducible factor 1alpha and induction of vascular endothelial growth factor in a rat neonatal stroke model[J]. Neurobiol Dis, 2003,14(3):524-534.